We validated the STAG2 and CDKN1A changes detected by whole-genome sequencing using Sanger sequencing in the discovery set of tumours, and then undertook replication testing in a set of 35 additional bladder cancers (Supplementary Table 3). This evidence concerns the gene STAG2 and neoplasm.